Welcome to Oxford Pharmascience Group Plc

Oxford Pharmascience is a drug development company that re-develops approved drugs using proprietary formulation technologies to make them better, safer and easier to take.

Since Oxford Pharmascience's products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company's pipeline is focused on pain relief and cardiovascular disease indications addressing unmet patient needs with significant commercial potential in global markets.


NSAID clinical development program

Developing improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs):

OXP001 - Reduced Gastric Irritation Ibuprofen

OXP002 - Single, high dose, better tasting Oral Suspension Ibuprofen (OXP002)

SafeStat™ clinical development program

Developing statins with higher efficacy and improved safety:

OXP003 - Atorvastatin

OXP004 - Simvastatin